Lonza's algae-derived DHAid line includes both oil and powdered products.
Lonza (Basel, Switzerland) has launched a vegetarian DHA omega-3 product line called DHAid, derived from algae. According to the company, the line offers advantages in stability and taste thanks to an “overall optimized fermentation process and improved productivity of the proprietary algal strain.”
The DHAid line includes two oil-based ingredients and one powdered ingredient. DHAid FNO-350 is a nutritional oil containing 350 mg DHA/g and is suited for food applications. The other oil ingredient, DHAid CL-400, is a clear oil offering 400 mg DHA/g and targets dietary supplements. Lonza says that both oil products are standardized with oleic sunflower oil to allow for a more precise calculation of the final DHA omgea-3 concentration in finished products.
The line’s powder ingredient is called DHAid Dry and is suited for applications in dry blends, such as nutrition beverages.
All ingredients are produced without the use of solvents. The company says that due to a controlled fermentation process, potential contaminants in marine sources, such as dioxins and heavy metals, are avoided.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.